You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pomalidomide

Showing 1 - 25 of 253
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bioequivalence Study Trial in Chennai (Pomalidomide 4 MG Oral Capsule)

Not yet recruiting
  • Bioequivalence Study
  • Pomalidomide 4 MG Oral Capsule
  • Chennai, Tamil Nadu, India
    Azidus Laboratories
Sep 22, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory Trial (Pomalidomide 4 mg every day in cycle 1,

Not yet recruiting
  • Multiple Myeloma in Relapse
  • +2 more
  • Pomalidomide 4 mg every day in cycle 1
  • +4 more
  • (no location specified)
Nov 16, 2022

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Myeloma Multiple, Myeloma, Refractory Multiple Myeloma Trial in Brooklyn, New York (Selinexor, Clarithromycin, Pomalidomide)

Terminated
  • Myeloma Multiple
  • +2 more
  • Brooklyn, New York
  • +1 more
Jan 24, 2023

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
Jan 9, 2023

Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Chapel Hill, North Carolina
  • +2 more
Jun 9, 2023

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

AL Amyloidosis Trial in Catanzaro, Pavia, Rome (daratumumab and pomalidomide)

Recruiting
  • AL Amyloidosis
  • daratumumab and pomalidomide
  • Catanzaro, Italy
  • +2 more
Aug 3, 2022

Multiple Myeloma Trial in United States (Pomalidomide, stem cell, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Pomalidomide
  • +3 more
  • Basking Ridge, New Jersey
  • +9 more
Jan 23, 2023

Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,

Active, not recruiting
  • Light Chain Deposition Disease
  • Primary Systemic Amyloidosis
  • pomalidomide
  • +3 more
  • Denver, Colorado
  • +4 more
Jan 20, 2023

Multiple Myeloma Trial in Lanzhou (Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Pomalidomide
  • Lanzhou, Gansu, China
    The First Hospital of Lanzhou University
Jul 9, 2022

Multiple Myeloma Trial in Seoul (Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Carfilzomib 56 MG [Kyprolis]
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
Aug 19, 2022

Multiple Myeloma Trial in Beijing, Qingdao (SPD:Selinexor Oral Tablet, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone
  • Beijing, Beijing, China
  • +1 more
Jul 26, 2022

Non-interventional Study With Pomalidomide (Imnovid®)

Completed
  • Multiple Myeloma
    • Freiburg, Baden-Wuerttemberg, Germany
      iOMEDICO AG
    Aug 11, 2022

    Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas Trial run by the NCI (Pomalidomide, Nivolumab)

    Recruiting
    • Viral Associated Malignancies
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 20, 2022

    Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (Daratumumab, Clarithromycin,

    Recruiting
    • Multiple Myeloma
    • +2 more
    • New York, New York
      Weill Cornell Medicine - Multiple Myeloma Center
    Jun 8, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jun 14, 2022

    Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Multiple Myeloma in Relapse
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Apr 13, 2022

    High Grade Squamous Intra-epithelial Lesion (HSIL) Trial in Darlinghurst (Pomalidomide 2 MG Oral Capsule [Pomalyst])

    Active, not recruiting
    • High Grade Squamous Intra-epithelial Lesion (HSIL)
    • Pomalidomide 2 MG Oral Capsule [Pomalyst]
    • Darlinghurst, New South Wales, Australia
      St Vincent's Hospital
    Mar 28, 2022

    Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia Trial in Chapel

    Recruiting
    • Acute Myeloid Leukemia
    • +5 more
    • Biospecimen Collection
    • +3 more
    • Baltimore, Maryland
    • +2 more
    Jan 19, 2023

    Multiple Myeloma Trial in Hackensack (Daratumumab, Pomalidomide, All-trans retinoic acid)

    Recruiting
    • Multiple Myeloma
    • Hackensack, New Jersey
      John Theurer Cancer Center
    Jun 10, 2022

    Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)

    Withdrawn
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Jan 26, 2023